Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Active Biotech, 24 Jan 2014
Accessed on 30 Jan 2014 from http://www.activebiotech.com/press-releases-1?pressurl=http://cws.huginonline.com/A/1002/PR/201401/1756936.xml.